Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 66% Improvement Relative Risk Case 9% Patil et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Prospective study of 9,212 patients in India Lower mortality with HCQ (not stat. sig., p=0.097) Patil et al., Research Square, doi:10.21203/ Favors HCQ Favors control
A Prospective Longitudinal Study Evaluating The Influence of Immunosuppressives and Other Factors On COVID-19 in Autoimmune Rheumatic Diseases
Patil et al., Research Square, doi:10.21203/ (Preprint)
Patil et al., A Prospective Longitudinal Study Evaluating The Influence of Immunosuppressives and Other Factors On COVID-19.., Research Square, doi:10.21203/ (Preprint)
Aug 2021   Source   PDF  
  All Studies   Meta
Prospective study of 9,212 autoimmune rheumatic disease patients showing lower mortality with HCQ, without reaching statistical significance. Authors incorrectly state "HCQ use did not influence occurrence of COVID-19 (RR = 0.909, CI (0.715,1.154), p = 0.432) or mortality (p = 0.097)" []. CFR for the autoimmune rheumatic disease patients was 4.6 times higher than in the general population from the same area.
risk of death, 65.9% lower, RR 0.34, p = 0.10, treatment 5,266, control 3,946.
risk of case, 9.1% lower, RR 0.91, p = 0.43, treatment 167 of 5,266 (3.2%), control 147 of 3,946 (3.7%), NNT 181, adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Patil et al., 24 Aug 2021, prospective, India, preprint, 20 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: A Prospective Longitudinal Study Evaluating The Influence of Immunosuppressives and Other Factors On COVID-19 in Autoimmune Rheumatic Diseases Abhishek Patil Manipal Hospital Chanakya K St. John’s Medical College Hospital Padmanabha Shenoy CARE Hospitals Chandrashekara S ChanRe Rheumatology and Immunology Centre Vikram Haridas Arthritis Superspeciality centre Sharath Kumar OARC Manisha Daware Narayana Health Ramya Janardana St. John’s Medical College Hospital Benzeeta Pinto St. John’s Medical College Hospital Ramaswamy Subramaniam JSS Medical College and Hospital Nagaraj S Columbia Asia Yogesh Preet Singh Manipal Hospital Shweta Singhai Sakra Hospital Ramesh Jois Vikram Hospital Vikramraj Jain Bhagwan Mahaveer Jain Hospital Page 1/20 Srinivasa C Fortis Hospital BG Dharmanand Vikram Hospital Chethana Dharmapalaiah Aster CMI Sangeetha KN Anagha Hospital Vijay K Rao Manipal Hospital Vineeta Shobha (  ) St. John’s Medical College Hospital Research Article Keywords: Autoimmune rheumatic diseases, SARS-CoV-2 infection, risk factors, outcome, hydroxychloroquine, glucocorticoid, immunosuppressants. DOI: License:   This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/20 Abstract Background We conducted this study to identify the influence of prolonged use of hydroxychloroquine(HCQ), glucocorticoids (GC) and other immunosuppressants (IS) on occurrence and outcome of COVID-19 in patients with autoimmune rheumatic diseases (AIRDs). Methods This was a prospective, multicenter, non-interventional longitudinal study across 15 specialist rheumatology centers. Consecutive AIRD patients on treatment with immunosuppressants were recruited and followed up longitudinally to assess parameters contributing to development of COVID-19 and its outcome. Results COVID-19 occurred in 314(3.45%) of 9212 AIRD patients during a median follow up of 177 (IQR 129,219) days. Long term HCQ use had no major impact on the occurrence or the outcome of COVID-19. Glucocorticoids in moderate dose (7.5-20mg/day) conferred higher risk (RR = 1.72) of infection. Among the IS, Mycophenolate mofetil (MMF), Cyclophosphamide (CYC) and Rituximab (RTX) use was higher in patients with COVID 19. However, the conventional risk factors such as male sex (RR = 1.51), coexistent diabetes mellitus (RR = 1.64), pre-existing lung disease (RR = 2.01) and smoking (RR = 3.32) were the major contributing risk factors for COVID-19. Thirteen patients (4.14%) died, the strongest risk factor being pre-existing lung disease (RR = 6.36, p = 0.01). Incidence ((17.5 vs 5.3 per 1 lakh (Karnataka) and 25.3 vs 7.9 per 1 lakh(Kerala) ) and case fatality (4.1% vs 1.3 % (Karnataka) and 4.3% vs 0.4% (Kerala)) rate of COVID-19 was significantly higher (p < 0.001) compared to the general population of the corresponding geographic region. Conclusions Immunosuppressants have a differential impact on the risk of COVID-19 occurrence in AIRD patients. Older age, males, smokers, hypertensive, diabetic and underlying lung disease contributed to higher risk. The incidence rate and the case fatality rate in AIRD patients is much higher than that in the general population. Key Message 1. Long term HCQ use had no major impact on the occurrence or the outcome of COVID-19 in AIRD. Page 3/20 2. Glucocorticoids in moderate doses increased the risk of COVID-19 in AIRD patients. 3. The incidence rate of..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop